AGTX.US Agentix Corp

Healthcare Biotechnology USA Stocks
0.0337 USD
Close of Nov 13, 2026
0.0142 0.0700
Market cap
USD 1.35M
P/E
-
P/B
3,587.45x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is AGTX.US undervalued?

Graham number

The Graham number of Agentix Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Agentix Corp fundamental analysis

No fundamental analysis for Agentix Corp yet.

Agentix Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Agentix Corp

Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fa…

Full company profile